Intech Medical (01501.HK) to Acquire Additional 0.79% Stake in Valgen Holding Corporation for USD 10 Million

(Zhitong Finance APP News) INT Medical (01501) announced that, in relation to the Company’s acquisition of approximately 23.18% of the total issued share capital of Valgen Holding Corporation, on June 25, 2026, the Company (as the buyer, or through its nominee) entered into a further share transfer agreement with certain existing shareholders of the target company (i.e., the sellers). The Company intends to acquire from the sellers 119,545 Series B preferred shares of the target company (the “Further Sale Shares”), representing approximately 0.79% of the total issued share capital of the target company, for a total consideration of US$10 million (equivalent to approximately RMB 68.209 million).

It is reported that the Target Company holds 100% of the equity interest in Valgen Medtech. The Target Company is a holding company with no substantive business activities. Valgen Medtech is primarily engaged in the research, development, manufacturing, and sales of interventional treatment technologies and products for atrioventricular valve diseases, particularly focusing on mitral and tricuspid valve interventions. Valgen Medtech serves as the principal operating entity of the Target Group in China. Four proprietary products developed by the Target Group have been included in the National Medical Products Administration’s (NMPA) Special Review Procedure for Innovative Medical Devices: the MitralStitch® Transapical Mitral Valve Repair System, the DragonFly™ Transcatheter Mitral Valve Clip System, the DragonFly-T® Transcatheter Tricuspid Valve Clip System, and the DragonFire® Transcatheter Radiofrequency Myocardial Ablation System. Among these, the DragonFly™ Transcatheter Mitral Valve Clip System is the first domestically produced transcatheter mitral valve product approved by the NMPA.

Upon the completion of both the first and second acquisitions, the Company will hold an aggregate of approximately 23.97% of the total issued share capital of the Target Company.

The Board of Directors believes that acquiring equity in the target company provides an opportunity to supplement the Company’s product pipeline in the field of structural heart disease, thereby achieving more comprehensive product coverage in this area and enhancing the Group’s overall competitiveness and long-term development potential in the cardiovascular intervention sector. The second acquisition aims to implement the Company’s strategy of gradually increasing its equity stake in the target company.